The Global Canine Arthritis Treatment Market, valued at USD 2.50 billion in 2024, is projected to experience steady growth over the next decade. According to industry forecasts, the market is expected to expand at a compound annual growth rate (CAGR) of 4.20%, reaching a valuation of USD 3.77 billion by 2034.
This growth reflects the increasing prevalence of arthritis in canines, driven by factors such as aging pet populations, rising pet ownership, and heightened awareness of pet health and wellness.
Key Market Drivers
- Rising Pet Ownership: An increase in pet adoption worldwide has significantly amplified the demand for veterinary care, including arthritis treatments.
- Aging Canine Population: With improved pet healthcare and longevity, conditions such as arthritis are becoming more common, necessitating effective treatment solutions.
- Innovation in Veterinary Pharmaceuticals: Development of advanced therapies, including pain management medications and regenerative treatments, is boosting market expansion.
Market Highlights
- 2024 Valuation: USD 2.50 billion
- 2034 Projection: USD 3.77 billion
- CAGR (2024-2034): 4.20%
Regional Insights
- North America: The largest market, supported by high pet healthcare expenditure, advanced veterinary infrastructure, and growing awareness about arthritis in pets.
- Europe: Demonstrating consistent growth with increasing adoption of specialized treatments for aging pets.
- Asia-Pacific: Emerging as a promising market due to rising pet ownership, improving veterinary healthcare systems, and increased awareness of animal health.
Treatment Trends
- Medications: Nonsteroidal anti-inflammatory drugs (NSAIDs) remain a cornerstone of canine arthritis treatment, while regenerative therapies like stem cell treatments are gaining traction.
- Lifestyle Support: Weight management and dietary supplements are being increasingly recommended alongside medications for comprehensive arthritis care.
Challenges
- Lack of awareness about canine arthritis symptoms in developing regions.
- Limited access to advanced veterinary care in rural areas.
Key Insights
The market for canine arthritis treatment encompasses various therapeutic approaches aimed at managing pain and inflammation associated with arthritis in dogs. The increasing prevalence of arthritis, particularly among aging dog populations, is a significant driver of market growth.
Growth Drivers
Several factors are contributing to the expansion of the canine arthritis treatment market:
- Rising Incidence of Arthritis in Dogs: The growing number of diagnosed cases due to factors such as obesity, age, and genetic predispositions is increasing demand for effective treatments.
- Advancements in Veterinary Medicine: Innovations in treatment options, including new medications and therapies, are enhancing the effectiveness of arthritis management.
- Increased Awareness Among Pet Owners: Greater awareness about pet health and wellness is encouraging owners to seek veterinary care for arthritis management.
Treatment Options
The canine arthritis treatment market includes various treatment types:
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs): These remain the cornerstone of pharmacological management, providing effective pain relief.
- Supplements: Products like glucosamine and chondroitin are gaining popularity among pet owners seeking alternative therapies.
- Surgical Options: In severe cases, surgical interventions may be considered to improve mobility and quality of life.
Competitive Landscape
Major companies and manufacturers in the canine arthritis treatment market, such as Boehringer Ingelheim International GmbH., DAIICHI SANKYO COMPANY, LIMITED, Thorne, NUTRI-VET, American Regent, Inc., DSM, etc., investing heavily in research and development to innovate new medications, supplements, and therapeutic approaches.
These companies are also expanding their distribution networks and partnerships with veterinary clinics, pet retailers, and online platforms to enhance the market reach and accessibility of their products to pet owners.
Recent Developments:
- In January 2023, TVM introduced DogStem, Europe’s inaugural licensed stem cell therapy for canine osteoarthritis. Clinical trials demonstrated its efficacy, with improvements in gait and orthopedic examination, and owners reported enhanced mobility and quality of life for their pets, lasting up to eighteen months.
- In May 2019, Elanco launched Galliprant, a new treatment for canine osteoarthritis pain, in the UK. Galliprant, a piprant, targets the EP4 receptor, reducing pain and inflammation without affecting gastrointestinal and kidney functions, offering a promising solution for managing OA discomfort in dogs.
- In February 2024, Rejuvenate Bio partnered with a leading animal health company to develop and commercialize groundbreaking gene therapy for canine osteoarthritis, aiming to address the condition’s widespread prevalence and devastating consequences, potentially revolutionizing dog health.
Key Companies in the Market
- Boehringer Ingelheim International GmbH
- DAIICHI SANKYO COMPANY, LIMITED
- Thorne
- NUTRI-VET
- American Regent, Inc.
- DSM
- Zoetis
- National hog farmer
- Novasep
- Bayer AG
- Matsun Nutrition
Get Complete Full Report
Canine arthritis treatment Market by Segmentation
By Treatment:
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Opioids
- Stem Cell Therapy
- Allogeneic Stem Cells
- Autologous Stem Cells
By Route of Administration:
- Oral Canine Arthritis Treatment
- Injectable Canine Arthritis Treatment
By Distribution Channel:
- Veterinary Hospitals & Clinics
- Retail Pharmacies
- Drug Stores
- e-Commerce
By Region:
- North America
- Latin America
- Asia Pacific
- Middle East and Africa (MEA)
- Europe
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube